<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03888625</url>
  </required_header>
  <id_info>
    <org_study_id>IMH2019</org_study_id>
    <nct_id>NCT03888625</nct_id>
  </id_info>
  <brief_title>Compare the Healing Process of Idiopathic Macular Hole With Different Surgical Techniques</brief_title>
  <official_title>Randomized Clinical Trials to Compare the Healing Process of Idiopathic Macular Hole With Different Surgical Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare anatomic and functional results, and to evaluate postoperatively the healing
      process in 2 different techniques for the closure of the macular holes (MH)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with macular holes classified in stages 3 and 4 will be randomized into 2 groups. .
      In Group A, patients will undergo peeling with complete removal of the internal limiting
      membrane (ILM) and in the group B, the inverted ILM peeling technique will be performed. The
      20% sulfur hexafluoride (SF6) gas will be used as a tamponade agent in all surgeries, and
      patients will be instructed to avoid the prone position for 5 days.

      OCT images will be performed in the first 5 postoperative days and months 1, 3 and 6.

      The primary outcome is anatomic closure of the MH closure in the month 6. The second outcomes
      are: mean best corrected visual acuity (BCVA) at month 6, mean change in the BCVA at month 6;
      integrity of the perifoveal external limiting membrane and ellipsoid zone on Optical
      Coherence Tomography (OCT); MH closure rate over time in days; functional improvement of
      microperimetry Statistical analysis will be performed with Student t-test and the p-value of
      ≤ 0.05 is considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In Group A, patients will undergo peeling with complete removal of the internal limiting membrane (ILM) and in the group B, the inverted ILM peeling technique will be performed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Anatomic closure</measure>
    <time_frame>Month 6 post operative</time_frame>
    <description>Rate of anatomic macular hole closure in the OCT at month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCVA mean</measure>
    <time_frame>Month 6 post operative</time_frame>
    <description>mean best corrected visual acuity (BCVA) at month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA change</measure>
    <time_frame>Screening and Month 6 post operative</time_frame>
    <description>change in the BCVA at month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integrity Membrane measured in microns (μm) by OCT</measure>
    <time_frame>Month 6 post operative</time_frame>
    <description>In the month 6, the area of discontinuity of the perifoveal external limiting membrane and ellipsoid zone in the OCT images will be measured in microns (μm) and correlated between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Macular Holes</condition>
  <arm_group>
    <arm_group_label>Group A: Conventional ILM peeling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>peeling with complete removal of the internal limiting membrane (ILM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GroupB: Inverted ILM Peeling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the inverted ILM peeling technique, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional ILM Peeling</intervention_name>
    <description>peeling with complete removal of the internal limiting membrane (ILM)</description>
    <arm_group_label>Group A: Conventional ILM peeling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inverted ILM Peeling</intervention_name>
    <description>the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange</description>
    <arm_group_label>GroupB: Inverted ILM Peeling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        &gt; Stage 3 and 4 macular holes with visual acuity between 20/30 and 20/800 according to the
        ETDRS chart.

        Exclusion Criteria:

          -  Macular holes secondary to ocular trauma, myopia or retinal detachment

          -  Any previous treatment for the macular hole

          -  Evidence on examination of any diabetic retinopathy

          -  History or presence of wet or dry age macular degeneration (AMD)

          -  Presence of epiretinal membrane or prior uveitis

          -  Any ocular surgery within 3 months before baseline

          -  Intra or periocular infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Maia, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mauricio Maia, MD, PhD</last_name>
    <phone>+55-18-991137727</phone>
    <email>maiamauricio@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luci p Silva, PhD, MBA</last_name>
    <phone>11971571967</phone>
    <email>luci.pesquisa@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Ophthalmology</name>
      <address>
        <city>São Paulo</city>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Maia, MD, PhD</last_name>
      <phone>1155764848</phone>
      <phone_ext>2265</phone_ext>
      <email>maiamauricio@terra.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Luci p Silva, PhD, MBA</last_name>
      <phone>11971571967</phone>
      <email>luci.pesquisa@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luiz Felipe A Lucatto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Octaviano Magalhães Júnior, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Muralha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alex Grupenmacher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Stefanini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muller G Urias, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maia Mauricio, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>March 22, 2019</last_update_submitted>
  <last_update_submitted_qc>March 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Mauricio Maia</investigator_full_name>
    <investigator_title>Professor of Ophthalmology Dept</investigator_title>
  </responsible_party>
  <keyword>macular holes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Perforations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

